Otsuka Holdings Co. (OTSKY) 16.1100 $OTSKY
Otsuka Enters Urology Field with Non-Invasive and Continuous Urine Volume Sensor Technology
Business Wire - Mon May 04, 1:53AM CDT
Lilium Otsuka Co., Ltd., an affiliated company of Otsuka Holdings Co., Ltd., (TOKYO:4578) announced that the National Institute of Advanced Industrial Science and Technology (AIST), UriCare Inc., and Lilium Otsuka signed a contract for research and development and marketing of products using ultrasound urinary volume sensor technology owned by UriCare and AIST.
FDA clears generic versions of Otsuka's Abilify antidepressant
Seeking Alpha - at Seeking Alpha - Tue Apr 28, 2:49PM CDT
TEVA: 60.19 (-0.04)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 12.42 (-0.34), FOMX: 11.36 (-0.05), PVCT: 0.85 (-0.02), JNJ: 103.42 (+1.12), DERM: 14.98 (+0.01), ANAC: 61.89 (-0.48), XNCR: 15.73 (+0.41), REGN: 496.74 (+7.73), AQXP: 7.44 (+0.10), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), VRX.TO: 270.02 (+2.67), CBPO: 103.18 (+1.62), MRK: 60.01 (-0.22), CCXI: 7.84 (+0.63), CLTX: 0.54 (-0.01), CELGZ: 2.60 (unch), NVS: 104.06 (+0.31)
How To Play Japanese Monopoly
Matthew Waterman - at Seeking Alpha - Tue Apr 21, 5:08AM CDT
SNE: 32.45 (-0.29), TM: 139.43 (+0.06), DCM: 18.39 (+0.11), MFG: 4.12 (+0.09), MAT: 26.28 (-0.67), SMFG: 8.85 (+0.19), S: 4.81 (-0.01), HMC: 35.20 (+0.20), MSFT: 48.01 (-0.28), KNM: 19.29 (+0.36), MTU: 7.60 (+0.37)
Phase 3 study shows efficacy of brexpiprazole in schizophrenia
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 9:32AM CDT
Tourette Syndrome Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 14, 11:02AM CDT
The report "Tourette Syndrome - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tourette Syndrome. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tourette-syn...eport.html .
NBIX: 43.14 (+1.51), CPRX: 3.41 (+0.09), ASPX: 100.96 (unch)
ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial
PR Newswire Europe - Fri Apr 10, 12:54PM CDT
ReCor Medical, Inc., a Palo Alto- and Amsterdam-based medical device firm, announced today a Series D investment of approximately $15M led by Otsuka Holdings Co., Ltd., the parent company of Otsuka Pharmaceutical and the Otsuka group of healthcare companies. Otsuka Holdings, one of the leading healthcare groups in Japan, joined Sofinnova Partners in the Series D round. In addition, ReCor has met with the US FDA regarding a new randomized controlled trial of its Paradise Renal Denervation ("RDN"
System in hypertensive patients to demonstrate its effect on blood pressure in conjunction with, and in the absence of, hypertensive drug therapy. The Company is planning to conduct the new study at 20 - 25 sites in the US and EU.
BSX: 18.06 (+0.21)
Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
DoctoRx - at Seeking Alpha - Thu Apr 09, 12:28AM CDT
BIIB: 395.42 (+4.18), MDCO: 26.92 (+0.57), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), LLY: 72.94 (+0.04), ABBV: 65.61 (-0.38), CELG: 116.37 (+0.84)
Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf6s4z/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" report to their offering. Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" provides data on the Polycystic Kidney Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polycystic Kidney Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polycystic Kidney Disease. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polycystic Kidney Disease Therapeutics Clinical Trials - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Kadmon Corporation, LLC - Daiichi Sankyo Company, Limited - XORTX Pharma Corp. - Novartis AG - GLG Pharma LLC For more information visit http://www.researchandmarkets.com/research/zf...tic_kidney
PFE: 33.98 (-0.01), NVS: 104.06 (+0.31)
Type 1 Diabetes, Progress With Stem Cells And Other Cell-Based Therapies
Keith Williams - at Seeking Alpha - Mon Mar 30, 2:05PM CDT
NVO: 56.92 (+0.17), AZN: 68.74 (-0.55), BMY: 68.00 (+0.36)
2015 could be the year of the blockbuster drug
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:26PM CDT
VRTX: 127.31 (+1.10), PFE: 33.98 (-0.01), AMGN: 163.44 (+1.08), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), ABBV: 65.61 (-0.38), THRX: 16.46 (+0.21), SNY: 50.40 (-0.12), REGN: 496.74 (+7.73), NVS: 104.06 (+0.31)
CHMP supports approval of Otsuka kidney disease drug
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 10:19AM CST
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 6.42 (+0.21), ITEK: 5.85 (+0.05), NBS: 2.37 (-0.01), FOMX: 11.36 (-0.05), AERI: 11.22 (-0.04), OCUL: 26.43 (+0.16), AGN: 240.22 (+2.88), CANF: 2.43 (+0.10), ACAD: 40.31 (+1.14), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), TEVA: 60.19 (-0.04), OHRP: 2.77 (+0.04), CBMG: 29.54 (+2.04)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 60.19 (-0.04), ITCI: 24.17 (+1.26), BCLI: 3.59 (-0.07), OMER: 20.99 (+0.11), NVS: 104.06 (+0.31)
Avanir's Drug-Device Combo Experiencing Minor FDA Headaches
Beacon VP Investments - at Seeking Alpha - Mon Dec 22, 1:41PM CST
AVNR: 16.96 (unch)
New Bidders Can Bring You High Return: Otsuka To Acquire Avanir
Maudes Capital - at Seeking Alpha - Tue Dec 02, 12:51PM CST
AVNR: 16.96 (unch)
Otsuka to buy US drugmaker Avanir for $3.5B
By The Associated Press - AP - Tue Dec 02, 6:06AM CST
Otsuka Pharmaceutical will spend $3.5 billion in cash to buy Avanir Pharmaceuticals in a deal that expands the Japanese drugmaker's portfolio of neurologic disease treatments.
AVNR: 16.96 (unch)
Wall Street Breakfast: Apple Heads To Trial Over iTunes Update
Wall Street Breakfast - Seeking Alpha - Tue Dec 02, 5:32AM CST
Economy Chinese stocks staged a late rally today amid speculation of more stimulus from the country's central bank. The Shanghai Composite Index climbed 3.1% , while the Hang Seng benchmark rose 1.2% . Oil has resumed declines as commodity...
VTNR: 3.33 (+0.37), MDT: 77.47 (+1.05), AV: 16.76 (-0.34), TFM: 34.46 (-0.06), GLW: 21.35 (+0.06), BA: 146.71 (-0.17), PCLN: 1,216.84 (+18.04), AVNR: 16.96 (unch), PERY: 27.55 (+0.79), SPY: 213.10 (+0.66), QQQ: 110.06 (+0.48), MSFT: 48.01 (-0.28), HMC: 35.20 (+0.20), AAPL: 130.19 (+1.42), HLSS: 0.67 (-16.51)
Otsuka to acquire Avanir for $17/share
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 2:44AM CST
AVNR: 16.96 (unch)
Otsuka Enters Urology Field with Non-Invasive and Continuous Urine Volume Sensor Technology
Business Wire - Mon May 04, 1:53AM CDT
Lilium Otsuka Co., Ltd., an affiliated company of Otsuka Holdings Co., Ltd., (TOKYO:4578) announced that the National Institute of Advanced Industrial Science and Technology (AIST), UriCare Inc., and Lilium Otsuka signed a contract for research and development and marketing of products using ultrasound urinary volume sensor technology owned by UriCare and AIST.
FDA clears generic versions of Otsuka's Abilify antidepressant
Seeking Alpha - at Seeking Alpha - Tue Apr 28, 2:49PM CDT
TEVA: 60.19 (-0.04)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 12.42 (-0.34), FOMX: 11.36 (-0.05), PVCT: 0.85 (-0.02), JNJ: 103.42 (+1.12), DERM: 14.98 (+0.01), ANAC: 61.89 (-0.48), XNCR: 15.73 (+0.41), REGN: 496.74 (+7.73), AQXP: 7.44 (+0.10), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), VRX.TO: 270.02 (+2.67), CBPO: 103.18 (+1.62), MRK: 60.01 (-0.22), CCXI: 7.84 (+0.63), CLTX: 0.54 (-0.01), CELGZ: 2.60 (unch), NVS: 104.06 (+0.31)
How To Play Japanese Monopoly
Matthew Waterman - at Seeking Alpha - Tue Apr 21, 5:08AM CDT
SNE: 32.45 (-0.29), TM: 139.43 (+0.06), DCM: 18.39 (+0.11), MFG: 4.12 (+0.09), MAT: 26.28 (-0.67), SMFG: 8.85 (+0.19), S: 4.81 (-0.01), HMC: 35.20 (+0.20), MSFT: 48.01 (-0.28), KNM: 19.29 (+0.36), MTU: 7.60 (+0.37)
Phase 3 study shows efficacy of brexpiprazole in schizophrenia
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 9:32AM CDT
Tourette Syndrome Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 14, 11:02AM CDT
The report "Tourette Syndrome - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tourette Syndrome. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tourette-syn...eport.html .
NBIX: 43.14 (+1.51), CPRX: 3.41 (+0.09), ASPX: 100.96 (unch)
ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial
PR Newswire Europe - Fri Apr 10, 12:54PM CDT
ReCor Medical, Inc., a Palo Alto- and Amsterdam-based medical device firm, announced today a Series D investment of approximately $15M led by Otsuka Holdings Co., Ltd., the parent company of Otsuka Pharmaceutical and the Otsuka group of healthcare companies. Otsuka Holdings, one of the leading healthcare groups in Japan, joined Sofinnova Partners in the Series D round. In addition, ReCor has met with the US FDA regarding a new randomized controlled trial of its Paradise Renal Denervation ("RDN"
System in hypertensive patients to demonstrate its effect on blood pressure in conjunction with, and in the absence of, hypertensive drug therapy. The Company is planning to conduct the new study at 20 - 25 sites in the US and EU. BSX: 18.06 (+0.21)
Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
DoctoRx - at Seeking Alpha - Thu Apr 09, 12:28AM CDT
BIIB: 395.42 (+4.18), MDCO: 26.92 (+0.57), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), LLY: 72.94 (+0.04), ABBV: 65.61 (-0.38), CELG: 116.37 (+0.84)
Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf6s4z/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" report to their offering. Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" provides data on the Polycystic Kidney Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polycystic Kidney Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polycystic Kidney Disease. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polycystic Kidney Disease Therapeutics Clinical Trials - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Kadmon Corporation, LLC - Daiichi Sankyo Company, Limited - XORTX Pharma Corp. - Novartis AG - GLG Pharma LLC For more information visit http://www.researchandmarkets.com/research/zf...tic_kidney
PFE: 33.98 (-0.01), NVS: 104.06 (+0.31)
Type 1 Diabetes, Progress With Stem Cells And Other Cell-Based Therapies
Keith Williams - at Seeking Alpha - Mon Mar 30, 2:05PM CDT
NVO: 56.92 (+0.17), AZN: 68.74 (-0.55), BMY: 68.00 (+0.36)
2015 could be the year of the blockbuster drug
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:26PM CDT
VRTX: 127.31 (+1.10), PFE: 33.98 (-0.01), AMGN: 163.44 (+1.08), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), ABBV: 65.61 (-0.38), THRX: 16.46 (+0.21), SNY: 50.40 (-0.12), REGN: 496.74 (+7.73), NVS: 104.06 (+0.31)
CHMP supports approval of Otsuka kidney disease drug
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 10:19AM CST
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 6.42 (+0.21), ITEK: 5.85 (+0.05), NBS: 2.37 (-0.01), FOMX: 11.36 (-0.05), AERI: 11.22 (-0.04), OCUL: 26.43 (+0.16), AGN: 240.22 (+2.88), CANF: 2.43 (+0.10), ACAD: 40.31 (+1.14), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), TEVA: 60.19 (-0.04), OHRP: 2.77 (+0.04), CBMG: 29.54 (+2.04)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 60.19 (-0.04), ITCI: 24.17 (+1.26), BCLI: 3.59 (-0.07), OMER: 20.99 (+0.11), NVS: 104.06 (+0.31)
Avanir's Drug-Device Combo Experiencing Minor FDA Headaches
Beacon VP Investments - at Seeking Alpha - Mon Dec 22, 1:41PM CST
AVNR: 16.96 (unch)
New Bidders Can Bring You High Return: Otsuka To Acquire Avanir
Maudes Capital - at Seeking Alpha - Tue Dec 02, 12:51PM CST
AVNR: 16.96 (unch)
Otsuka to buy US drugmaker Avanir for $3.5B
By The Associated Press - AP - Tue Dec 02, 6:06AM CST
Otsuka Pharmaceutical will spend $3.5 billion in cash to buy Avanir Pharmaceuticals in a deal that expands the Japanese drugmaker's portfolio of neurologic disease treatments.
AVNR: 16.96 (unch)
Wall Street Breakfast: Apple Heads To Trial Over iTunes Update
Wall Street Breakfast - Seeking Alpha - Tue Dec 02, 5:32AM CST
Economy Chinese stocks staged a late rally today amid speculation of more stimulus from the country's central bank. The Shanghai Composite Index climbed 3.1% , while the Hang Seng benchmark rose 1.2% . Oil has resumed declines as commodity...
VTNR: 3.33 (+0.37), MDT: 77.47 (+1.05), AV: 16.76 (-0.34), TFM: 34.46 (-0.06), GLW: 21.35 (+0.06), BA: 146.71 (-0.17), PCLN: 1,216.84 (+18.04), AVNR: 16.96 (unch), PERY: 27.55 (+0.79), SPY: 213.10 (+0.66), QQQ: 110.06 (+0.48), MSFT: 48.01 (-0.28), HMC: 35.20 (+0.20), AAPL: 130.19 (+1.42), HLSS: 0.67 (-16.51)
Otsuka to acquire Avanir for $17/share
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 2:44AM CST
AVNR: 16.96 (unch)
